BAY-79-4620 Antibody
BAY-79-4620 Antibody is a potent and selective CAIX antibody with a human CAIX Kd of 3.6 nM. BAY-79-4620 Antibody yields antibody-drug conjugate (ADC) through conjugating with Monomethyl auristatin E (HY-15162) via a self-immolative enzyme-cleavable linker. BAY-79-4620 Antibody can be used for the research of cervical carcinoma, non-small cell lung carcinoma, breast carcinoma, pancreatic carcinoma, gastric carcinoma, prostate carcinoma.
For research use only. We do not sell to patients.
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Human
|
hCA IX 3.6 nM (Kd) |
BAY-79-4620 Antibody binds selectively to the purified human CAIX ectodomain with a high affinity (Kd = 3.6 nM)[1].
BAY-79-4620 Antibody (25 μg/mL; 1 hour on ice) selectively binds to CAIX-positive PC-3mm2 and MiaPaCa-2-CAIX cells, with no binding to CAIX-negative MiaPaCa-2 cells[1].
BAY-79-4620 Antibody (72 h) potently kills CAIX-positive MiaPaCa-2-CAIX cells with an IC50 of 10 nM via tubulin disruption through conjugating with Monomethyl auristatin E, while CAIX-negative MiaPaCa-2 cells are highly resistant[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
BAY-79-4620 Antibody (0.625-10 mg/kg; i.v.; 3 doses every 4 days) exhibits potent, dose-dependent antitumor efficacy against HT-29 colorectal carcinoma xenografts in immunocompromised mice after conjugating with Monomethyl auristatin E[1].
BAY-79-4620 Antibody (0.625-60 mg/kg; i.v.; 3 doses every 4 days) is highly active against HeLa-MaTu cervical carcinoma xenografts in immunocompromised mice after conjugating with Monomethyl auristatin E[1].
BAY-79-4620 Antibody (i.v.; 3 doses every 4 days) dose-dependently inhibits growth of PC3mm2 prostate carcinoma xenografts in immunocompromised mice after conjugating with Monomethyl auristatin E[1].
BAY-79-4620 Antibody (60 mg/kg; i.v.; 3 doses every 4 days) exhibits significant antitumor activity against NCI-N87 gastric carcinoma xenografts in immunocompromised mice after conjugating with Monomethyl auristatin E[1].
BAY-79-4620 Antibody (1-60 mg/kg; i.v.; 3 doses every 4 days) exhibits significant antitumor activity against patient-derived non-small cell lung carcinoma xenografts in NMRI nu/nu mice after conjugating with Monomethyl auristatin E[1].
BAY-79-4620 Antibody (0.625-5 mg/kg; i.v.; 3 doses every 4 days) is inactive against multidrug-resistant HCT-15 colorectal carcinoma xenografts in immunocompromised mice after conjugating with Monomethyl auristatin E[1].
BAY-79-4620 Antibody (i.v.; 3 doses every 4 days) antitumor efficacy in immunocompromised mice correlates positively with tumor CAIX expression levels after conjugating with Monomethyl auristatin E[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Immunocompromised mice (8-12 weeks of age)[1]
-
Dosage:2.5 mg/kg; 5 mg/kg; 10 mg/kg
-
Administration:i.v.
-
Result:Yielded tumor growth inhibition (TGI) of 63%, 82%, and 94% at doses of 2.5, 5, and 10 mg/kg, respectively.
Produced 100% tumor shrinkage at the 10 mg/kg dose.
Exhibited minimal TGI (≤50%) at 10 mg/kg in mice implanted with CAIX-negative MiaPaCa-2 tumors.
-
Animal Model:Immunocompromised mice (8-12 weeks of age)[1]
-
Dosage:0.625 mg/kg; 1.25 mg/kg; 2.5 mg/kg; 5 mg/kg; 10 mg/kg
-
Administration:i.v. 3 doses every 4 days
-
Result:Yielded transient antitumor activity with single-dose administration.
Produced TGI of 54%, 72%, 97%, 100%, and 100% at doses of 0.625, 1.25, 2.5, 5, and 10 mg/kg with 3 doses every 4 days schedule.
Induced tumor regression in 20% (1.25 mg/kg), 90% (2.5 mg/kg), 100% (5 mg/kg), and 100% (10 mg/kg) of tumors with 3 doses every 4 days schedule.
Showed increased G2/M arrest, multipolar spindles, and decreased tubulin levels by day 1 post-single dose, with near-universal cellular damage by day 5 in the 5 mg/kg group.
Was well tolerated with no weight loss at all doses.
-
Animal Model:Immunocompromised mice (8-12 weeks of age)[1]
-
Dosage:0.625 mg/kg; 1.25 mg/kg; 2.5 mg/kg; 60 mg/kg
-
Administration:i.v.; 3 doses every 4 days
-
Result:Showed a minimal effective dose of 0.625 mg/kg.
Caused 80% of tumors to exhibit shrinkage at 1.25 mg/kg.
Induced 100% of tumors to show regression or complete regression at doses ≥2.5 mg/kg.
Produced 10% lethality and 20% body weight loss (maximum tolerated dose) at 60 mg/kg, while all lower doses were well tolerated.
-
Animal Model:Immunocompromised mice (8-12 weeks of age)[1]
-
Dosage:60 mg/kg
-
Administration:i.v.; 3 doses every 4 days
-
Result:Produced significant antitumor efficacy.
-
Animal Model:NMRI nu/nu mice[1]
-
Dosage:1 mg/kg; 3 mg/kg; 10 mg/kg; 30 mg/kg; 60 mg/kg
-
Administration:i.v.; 3 doses every 4 days
-
Result:Exhibited significant antitumor efficacy across heterogeneous tumor models (containing both CAIX-positive and CAIX-negative cells), consistent with a bystander effect.
Showed high efficacy in the Lu7406 model.
-
Animal Model:Immunocompromised mice (8-12 weeks of age)[1]
-
Dosage:0.625 mg/kg; 1.25 mg/kg; 2.5 mg/kg; 5 mg/kg
-
Administration:i.v.; 3 doses every 4 days
-
Result:Was inactive against HCT-15 tumors, which overexpress P-glycoprotein.
CA9/CAIX
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Product Image
ELISA, FACS, Functional assay
Chemical Information
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
BAY-79-4620 Antibody Related Classifications
HY-P992322 Related Classifications
Powered by Bioz